Related Experiment Video
Updated: Jun 9, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
[Multiple system atrophy]
Nathalie Damon-Perrière1, François Tison, Wassilios G Meissner
1Service de neurologie, Centre de référence national maladie rare atrophie multisystématisée, CHU de Bordeaux, Hôpital du Haut-Lévêque, Pessac.
Abstract:
Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder of unknown etiology. It is the most frequent disorder among atypical parkinsonism with an estimated prevalence of 2 to 5 per 100 000 inhabitants. The clinical symptoms are rapidly progressing with a mean survival ranging between 6 to 9 years. The diagnosis is based on consensus criteria that have been revised in 2008. The diagnostic criteria allow defining "possible", "probable" and "definite" MSA. The latter requires post mortem confirmation of striatonigral and olivopontocerebellar degeneration with alpha-synuclein containing glial cytoplasmic inclusions. The diagnosis of "possible" and "probable" MSA is based on the variable presence and severity of parkinsonism, cerebellar dysfunction, autonomic failure and pyramidal signs. According to the revised criteria, atrophy of putamen, pons, middle cerebellar peduncle (MCP) or cerebellum on brain magnetic resonance imaging are considered to be additional features for the diagnosis of "possible" MSA. T2-weighted brain imaging may further reveal a putaminal hypointensity, a hyperintense lateral putaminal rim, the so called "hot cross bun sign" and MCP hyperintensities. Cardiovascular examination, urodynamic testing and anal sphincter electromyography may be helpful for the diagnosis of autonomic failure. Some patients may respond to levodopa, but usually to a lesser extent than those suffering from Parkinson's disease, and high doses are already required in early disease stages. No specific therapy is available for cerebellar dysfunction, while effective treatments exist for urinary and cardiovascular autonomic failure. Physical therapy may help to improve the difficulties of gait and stance, and to prevent their complications. In later disease stages, speech therapy becomes necessary for the treatment of dysarthria and dysphagia. Percutaneous gastrostomy is sometimes necessary in patients with severe dysphagia. Beyond these strategies, psychological support, social care and occupational therapy to adapt the environment to the patient's disability are prerequisites for improving the quality of life in MSA patients.
Insights
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative disease. Diagnosis relies on clinical symptoms and imaging, with supportive care improving quality of life.
Area of Science:
- Neuroscience
- Neurology
- Pathology
Context:
- Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder with unknown etiology.
- It is the most frequent disorder among atypical parkinsonism, affecting 2-5 per 100,000 inhabitants.
- Characterized by rapidly progressing clinical symptoms and a mean survival of 6-9 years.
Purpose:
- To outline the diagnostic criteria for Multiple System Atrophy (MSA).
- To describe the clinical presentation, diagnostic features, and management strategies for MSA.
- To highlight the importance of supportive care in improving the quality of life for MSA patients.
Summary:
- Diagnosis of MSA is based on revised 2008 consensus criteria, categorizing cases as "possible", "probable", or "definite".
- Definite MSA requires post-mortem confirmation of specific neuropathological findings.
- "Possible" and "probable" diagnoses rely on the presence and severity of parkinsonism, cerebellar dysfunction, autonomic failure, and pyramidal signs.
- Brain MRI findings like putaminal atrophy, "hot cross bun sign", and MCP hyperintensities aid diagnosis.
- Autonomic function testing (cardiovascular, urodynamic, anal sphincter EMG) is crucial for diagnosing autonomic failure.
- While levodopa may offer limited benefit, specific therapies exist for autonomic dysfunction, and physical, speech, and occupational therapies are vital for symptom management and quality of life.
Impact:
- Improved diagnostic accuracy for Multiple System Atrophy (MSA).
- Enhanced understanding of MSA's clinical spectrum and progression.
- Provides a framework for multidisciplinary management and supportive care strategies to improve patient outcomes and quality of life.
Related Concept Videos
Multiple Sclerosis l: Introduction
Myasthenia Gravis ll: Pathophysiology
Alzheimer Disease ll: Pathophysiology
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Alterations in Muscle Tone lll
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

